Kennedy’s Plan for the Drug Crisis: A Network of ‘Healing Farms’
The positions of Robert F. Kennedy Jr. on vaccines and drug companies are well known. His approach to addiction has been far ...
Red dye No. 3 is now banned in the US. Here’s what studies show about more common dyes
Following the ban of red dye No. 3 in the United States, experts weigh in on the potential health risks of red dye No. 40, ...
JD Supra2d
FDA announces public meeting on pediatric exclusivity and drug development
Earlier this month, the U.S. Food and Drug Administration (FDA) announced a public meeting entitled “Interested Parties Meeting: Implementation of ...
Healthcare Dive2d
Ozempic among drugs picked by Medicare for price talks
Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...
BioPharma Dive2d
Ozempic, Ibrance among next drugs picked by Medicare for price talks
Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...
frontpageafricaonline3d
Liberia: FDA Pays Board Member Living in America
MONROVIA – The Forestry Development Authority (FDA) pays a member of its board of directors who lives in the United States ...
FiercePharma3d
Government watchdog recommends tweaks to FDA accelerated approval program
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
MedPage Today3d
HHS Inspector General Raises Concerns Over FDA's Accelerated Approvals
Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...
Becker's Hospital Review4d
Watchdog flags flaws in FDA's fast-track drug approvals
The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...